Eton Pharmaceuticals Inc (ETON)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

21925 W. FIELD PARKWAY DEER PARK, IL 60010-7208

Eton Pharmaceuticals, Inc. operates as a development stage biotechnology company. The Company develops sterile injectable drug candidate pipeline. Eton Pharmaceuticals serves patients in the State of California.

View SEC Filings from ETON instead.
Q2 2019 All Institutions Hedge Funds 1
To trade ETON now:
Filers who had this stock in their top 10: 0 0 (0.0%)
13F Filers holding this stock: 11 3 (0.31%)
Aggregate 13F shares on 06/30/2019: 1.768 Million 1.556 Million
Aggregate 13F shares on 03/31/2019: 1.501 Million 1.227 Million
Percent change: 17.77% 26.85%
Funds creating new positions: 1
Funds Adding to an existing position: 6 2
Funds closing out their position: 3
Funds reducing their position: 1
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ETON (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

8.5 Thousand total shares from 2 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BRYNJELSEN SEAN PRESIDENT & CEO

  • Officer
  • Director
1,049,940 2019-08-13 5

CASAMENTO CHARLES J

  • Director
71,920 2019-08-09 4

RIEDEL NORBERT G

  • Director
7,685 2019-08-08 3

MAIER PAUL V

  • Director
0 2019-06-03 3

TROUTMAN WILLIAM WILSON CFO, TREASURER & SECRETARY

  • Officer
0 2019-02-20 3

BAUM MARK L

  • Director
0 2019-02-20 3

IMPRIMIS PHARMACEUTICALS, INC.

  • 10% Owner
3,500,000 2018-11-09 1

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

BRYNJELSEN SEAN - Director - Officer PRESIDENT & CEO

2019-08-13 P 5,000 $6.15 a 1,025,000 1,049,940.00 direct

CASAMENTO CHARLES J - Director

2019-08-09 P 3,500 $6.11 a 71,920 71,920.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments